Provided by Tiger Trade Technology Pte. Ltd.

Caribou Biosciences

1.25
-0.0200-1.57%
Post-market: 1.260.0100+0.80%17:57 EDT
Volume:968.63K
Turnover:1.23M
Market Cap:133.75M
PE:-1.16
High:1.29
Open:1.28
Low:1.25
Close:1.27
52wk High:3.54
52wk Low:1.25
Shares:107.00M
Float Shares:102.16M
Volume Ratio:0.55
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0751
EPS(LYR):-1.5900
ROE:-78.27%
ROA:-36.84%
PB:1.36
PE(LYR):-0.79

Loading ...

Caribou reports durable responses in phase 1 CaMMouflage trial of CB-011 CAR-T in relapsed multiple myeloma

Reuters
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Caribou Biosciences CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Caribou Biosciences (CRBU) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 27

May 2026's Promising Penny Stocks

Simply Wall St.
·
May 14

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

GlobeNewswire
·
May 14

Caribou Biosciences to present vispa-cel data at EHA annual meeting

Reuters
·
May 12

Caribou Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

Caribou Biosciences, Inc. : H.c. Wainwright Raises Target Price to $11 From $9

THOMSON REUTERS
·
May 11

U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla

Reuters
·
May 11

Caribou Biosciences (CRBU) Gets a Buy from Citi

TIPRANKS
·
May 10

Caribou Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 09

Caribou aligns with FDA on ANTLER-3 phase 3 vispa-cel trial design in 2L LBCL

Reuters
·
May 08

Caribou Biosciences Q1 FY26 net loss narrows to $25.09 million; R&D expenses drop to $20.61 million

Reuters
·
May 08

Caribou Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 07

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

GlobeNewswire
·
May 06

Caribou Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 02

Caribou Biosciences announces annual shareholder meeting notice

Reuters
·
Apr 11

Caribou Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 07

Caribou says FDA grants RMAT designation to CB-011 allogeneic BCMA CAR-T therapy

Reuters
·
Apr 01